A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

About the study

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or "parts." * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with MDS. * Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with AML. * Part D will find out how much SEA-CD70 with azacitidine should be given to participants * Part E will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML that has not been treated. * Part F will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML. * Part G will find out how much SEA-CD70 with azacitidine and with venetoclax should be given to participants with AML. Also, to evaluate safety and tolerability of PF-08046040 in combination with azacitidine and venetoclax in participants with previously untreated AML who are unfit for standard induction chemotherapy.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Part A Inclusion Criteria

* Participants with cytologically/histologically confirmed MDS (2016 World Health Organization (WHO) classification) with

Measurable disease per WHO MDS with excess blasts criteria
MDS that is relapsed or refractory and must not have other therapeutic options
Treatment failure after prior hypomethylating agent (HMA) therapy for MDS
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

Part B Inclusion Criteria

* Participants with cytologically/histologically confirmed MDS (WHO classification) with:

Measurable disease per WHO MDS with excess blasts (MDS-EB) criteria
MDS that is relapsed or refractory and must not have other therapeutic options
Treatment failure after prior HMA therapy for MDS
ECOG Performance Status of 0-2

Part C Inclusion Criteria

* Participants with relapsed or refractory AML (ICC 2022) (except for acute promyelocytic leukemia [APL]):

Who have received either 2 or 3 previous regimens
Who have received 1 previous regimen to treat active disease and have at least one of the following:

Age > 60 and ≤75 years.
Primary resistant AML or secondary AML
First CR duration <6 months
Adverse-risk per European Leukemia Network genetic risk stratification
Age 18-75 years
ECOG performance status of 0-2

Parts D and F Inclusion Criteria

Participants with diagnosis of MDS or MDS/AML (ICC 2022 criteria)
Disease which has relapsed, failed to respond after minimum of 6 cycles, or progressed following an HMA in the immediately preceding line of therapy.
Eligible for continued therapy with azacitidine
ECOG Performance Status 0-2

Parts D and E Inclusion Criteria

Participants with diagnosis of MDS or MDS/AML (ICC 2022 criteria), previously untreated.
Participants with higher-risk per IPSS-M MDS and MDS/AML
ECOG Performance Status 0-2

Part G Inclusion Criteria

Participants with diagnosis of AML (ICC 2022 criteria), previously untreated and ineligible for standard induction chemotherapy.
Age ≥18 years.
ECOG Performance Status of 0-2.

EXCLUSION CRITERIA

Exclusion Criteria (All Parts)

Previous exposure to CD70-targeted agents
Prior allogeneic hematopoietic stem cell transplant, for any condition
Central nervous system leukemia
History of clinically significant sickle cell anemia, autoimmune hemolytic anemia, or idiopathic thrombocytopenic purpura
Parts D, F and G only: Prior oral HMA or oral HMA-combinations
Part G: conditions that preclude enteral route of administration; concomitant use of strong/moderate CYP3A inducers; history of myeloproliferative neoplasm